Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| LGD-4033 (Ligandrol) | RAD-140 (Testolone) | |
|---|---|---|
| Category | SARMs | SARMs |
| Standard Dose | Research indicates 5-10 mg daily orally for 8-12 weeks. Phase 1 data showed significant lean mass gains at 1 mg/day. | Research indicates 10-20 mg daily orally for 8-12 weeks. Phase 1 clinical trial (oncology) identified 100 mg as the maximum tolerated dose. |
| Timing | Once daily, consistent timing. Half-life approximately 24-36 hours. No food timing requirements. | Once daily, consistent timing. Very long half-life (~60 hours) means stable plasma levels even with once-daily dosing. Morning preferred. |
| Cycle Duration | 8-12 week cycles maximum. PCT strongly recommended after all but the shortest/lowest-dose cycles. | 8-12 week cycles. PCT mandatory due to significant HPG axis suppression. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
LGD-4033 is a potent nonsteroidal selective androgen receptor modulator with high AR binding affinity (Ki of approximately 1 nM). It demonstrates strong anabolic activity in muscle and bone with significantly reduced androgenic activity in prostate tissue, achieving an anabolic-to-androgenic ratio of approximately 10:1. LGD-4033 activates the AR with full agonist efficacy in muscle, upregulating the PI3K/Akt/mTOR pathway for protein synthesis and satellite cell recruitment. It produces dose-dependent suppression of SHBG, total testosterone, LH, and FSH, indicating significant HPG axis suppression even at low doses.
Research indicates 5-10 mg daily orally for 8-12 weeks. Phase 1 data showed significant lean mass gains at 1 mg/day.
Once daily, consistent timing. Half-life approximately 24-36 hours. No food timing requirements.
8-12 week cycles maximum. PCT strongly recommended after all but the shortest/lowest-dose cycles.
RAD-140 is a potent nonsteroidal SARM with high oral bioavailability and selectivity for muscle and bone AR over prostate. It acts as a full agonist at the AR in muscle tissue, promoting nitrogen retention and protein synthesis via mTOR/p70S6K pathway activation. RAD-140 also demonstrates neuroprotective properties, acting against beta-amyloid-induced neurotoxicity through AR-mediated MAPK/ERK signaling. Preclinical data show greater anabolic potency than testosterone propionate at equivalent doses with significantly reduced prostate stimulation.
Research indicates 10-20 mg daily orally for 8-12 weeks. Phase 1 clinical trial (oncology) identified 100 mg as the maximum tolerated dose.
Once daily, consistent timing. Very long half-life (~60 hours) means stable plasma levels even with once-daily dosing. Morning preferred.
8-12 week cycles. PCT mandatory due to significant HPG axis suppression.
Fast buy links (we may earn a small commission at no extra cost).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →